Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 20,300 shares, a decline of 20.4% from the November 15th total of 25,500 shares. Based on an average daily volume of 6,900 shares, the short-interest ratio is presently 2.9 days.

Pharming Group Stock Performance

PHAR traded down $0.34 on Friday, reaching $8.98. The company had a trading volume of 2,978 shares, compared to its average volume of 5,220. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20. The stock has a market cap of $609.31 million, a P/E ratio of -34.55 and a beta of 0.05. The company’s fifty day moving average is $8.27 and its 200 day moving average is $8.13. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Wednesday. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Oppenheimer lowered their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.